Compounded GLP-1: What It Is, Why It Exists, and Whether to Trust It
Compounded GLP-1s are not FDA-approved or independently tested for purity. During the 2023–2024 shortage they were legal under temporary FDA rules; many sellers still operate in a gray zone. Brand-name product is the only fully validated option. If you use a compounded version, vet the pharmacy, never buy from social media, and watch for counterfeits.
Compounded GLP-1 medications became widely available in 2023 when the FDA listed both semaglutide and tirzepatide as in shortage. Under federal law, this allowed compounding pharmacies to make their own versions. The market exploded, and so did the problems.
What "compounded" means
Compounded medications are mixed by licensed compounding pharmacies on a per-prescription basis. They are not FDA-approved. They do not go through the safety, efficacy, or manufacturing-quality review that brand-name drugs do.
Compounding is legal and often necessary — for example, when a patient needs a non-standard dose, a sterile-injection kid's formulation, or a drug not available commercially. But during the GLP-1 shortage, compounding became a back-door for mass-market production of drugs that were "officially unavailable."
Why the shortage exists/existed
Demand for semaglutide and tirzepatide outstripped Novo Nordisk and Eli Lilly's manufacturing capacity. The FDA's shortage list triggered a temporary rule allowing 503A and 503B compounders to make these drugs. As supplies have caught up, the FDA has been moving to remove tirzepatide and semaglutide from the shortage list, ending the legal cover for most compounding.
The risks
Variable purity. Compounded products are not subject to the same testing as brand-name. Independent testing has found:
- Wide dose variation between vials
- Bacterial or endotoxin contamination
- "Salt forms" of semaglutide (semaglutide sodium, semaglutide acetate) that the FDA has explicitly stated are not the same drug as semaglutide
Counterfeits. Especially in the gray market: random websites, social media sellers, "wellness" clinics with no medical oversight. Counterfeit pens have been found containing insulin, sugar water, or unknown peptides.
No safety reporting. When something goes wrong with a compounded product, there is no central adverse event database. The FDA can't track problems they don't see.
Loss of effectiveness. Some compounded "semaglutide" lots have tested at a fraction of labeled potency. You may be paying for a drug that's barely working.
When compounded is reasonable
If you are going to use a compounded GLP-1, vet the pharmacy:
- Licensed compounding pharmacy — verify the state pharmacy board license, not just a website claim.
- Prescription required — any source that ships without one is unsafe and likely illegal.
- USP-797 sterile compounding — the standard for injectables.
- Independent testing/COAs — better pharmacies provide certificates of analysis on each lot.
- Relationship with a real prescriber — not a "telehealth" portal that prescribes everyone everything.
What to avoid completely
- Social media sellers (Instagram, TikTok, Reddit DMs)
- Sellers that don't require a prescription
- "Research peptides" sold for "non-human use" — illegal repackaging
- Anyone shipping from outside the U.S.
- Prices that seem dramatically below market (counterfeit signal)
The brand-name reality
If you can afford brand-name, take it. Manufacturer direct-pay programs (Lilly Direct for Zepbound; Novo Nordisk's NovoCare for Wegovy) have cash prices for self-pay patients that are dramatically lower than list, and have made brand-name product more accessible. The peace of mind of knowing exactly what is in your pen is worth a lot.
Bottom line
Compounded GLP-1s exist in a regulatory gray zone, with real safety variability and counterfeit risk. They are not equivalent to brand-name product. If you have a choice, choose brand-name. If you must use compounded, vet the pharmacy carefully and never buy from social media.